Loading...
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee, F Wong, R Munshi, N Rossi, J Ke, X Fosså, A Simpson, D Capra, M Liu, T Hsieh, R
van Rhee, F
Wong, R
Munshi, N
Rossi, J
Ke, X
Fosså, A
Simpson, D
Capra, M
Liu, T
Hsieh, R
Citations
Altmetric:
Abstract
Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated production of interleukin 6. No randomised trials have been done to establish the best treatment for the disease. We assessed the safety and efficacy of siltuximab-a chimeric monoclonal antibody against interleukin 6-in HIV-negative patients with multicentric Castleman's disease.
Description
Date
2014-08
Publisher
Collections
Keywords
Type
Article
Citation
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. 2014, 15 (9):966-74 Lancet Oncol